Key facts
- Vilya’s last known valuation is $144.0M.
- It has raised $73.8M; the latest was Early Stage VC ($71.0M) in Jun 2024.
- Notable investors include Menlo Ventures, Madrona Venture Group, ARCH Venture Partners, NVentures (Santa Clara), Lifeforce Capital — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Vilya
- ·The full record, as it builds
Funding rounds
No funding rounds for Vilya are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Vilya
Developer of a biotechnology platform designed to create medicines that precisely target disease biology. The company's platform builds molecular structures that range in size and antibodies, with critical drug-like properties, including the ability to move through biological membranes and to disrupt protein interactions, enabling doctors to effectively treat patients.
- Sector
- Healthcare
- HQ
- Seattle, WA, United States
- Founded
- 2022
- Employees
- 49
- Website
- vilyatx.com/
- Ownership
- Privately Held (backing)
Vilya doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Vilya shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Vilya in its N-PORT filings yet. We sweep new filings monthly.